A new clinical trial from Scripps Research in La Jolla, California, United States, aims to make significant gains in the global fight against malaria by making a drug that has been around since the 1970s last longer.
Working with a contract drug manufacturing and testing firm in Britain, 25 to 30 healthy volunteers are starting to receive the first doses of a new drug that is a long-acting enhancement of atovaquone, which is part of a once-daily, malaria-prevention combination medication often prescribed to travellers.
